Logo
x

Search

Subscribe Now

CFDA

BioMarin's Vimizim (elosulfase alfa) Receives NMPA's (CFDA) Approval for Treatment of Morquio A Syndrome

BioMarin's Vimizim (elosulfase alfa) Receives NMPA's (CFDA) Approval for Treatment of Morquio A Syndrome

  • June 5, 2019
Merck's Keytruda (pembrolizumab) + Chemotherapy Receive NMPA's (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck's Keytruda (pembrolizumab) + Chemotherapy Receive NMPA's (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung...

  • April 2, 2019
Novartis' Cosentyx (secukinumab) Receives NMPA's (CFDA) Approval for Patients with Plaque Psoriasis in Adults

Novartis' Cosentyx (secukinumab) Receives NMPA's (CFDA) Approval for Patients with Plaque Psoriasis in Adults

  • April 2, 2019
Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

Biogen's Spinraza (nusinersen) Receives NMPA (CFDA) Approval for Spinal Muscular Atrophy (SMA) Aged 6wks.

  • March 1, 2019
Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia

Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia

  • January 30, 2019
Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab- biosimilar) from NMPA (CFDA) to Treat NSCLC

Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab- biosimilar) from NMPA (CFDA) to Treat NSCLC

  • January 29, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.